Markets:

Overview

News

Currencies

International

Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

3.250 -0.050 (-1.52%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

August 10, 2023

From Nkarta, Inc.

Via GlobeNewswire

3 Hidden Penny Stocks That Could Turn $100 into $10,000 ↗

July 31, 2023

These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts.

Via InvestorPlace

Analyst Expectations for Nkarta's Future ↗

June 27, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 07, 2023

On Thursday, 283 companies set new 52-week lows.

Via Benzinga

The Latest Analyst Ratings for Nkarta ↗

August 10, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

July 05, 2023

Wednesday's session saw 43 companies set new 52-week lows.

Via Benzinga

NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline ↗

June 27, 2023

Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 27, 2023

Via Benzinga

Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 27, 2023

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health.

Via Benzinga

Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors ↗

June 27, 2023

Nkarta Inc (NASDAQ: NKTX) announced updated data from the Phase 1 study of NKX101 to treat patients with relapsed or refractory (r/r)

Via Benzinga

Why Shares of Nkarta Are Slumping Tuesday ↗

June 27, 2023

The pharmaceutical stock dropped after announcing so-so clinical trial results.

Via The Motley Fool

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

June 27, 2023

From Nkarta, Inc.

Via GlobeNewswire

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

June 26, 2023

Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET

From Nkarta, Inc.

Via GlobeNewswire

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

June 10, 2023

From Nkarta, Inc.

Via GlobeNewswire

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023

From Nkarta, Inc.

Via GlobeNewswire

7 Stocks With Promising Upside Potential for 100% Returns ↗

May 07, 2023

If you still want to gamble even during this market environment, these are the stocks with 100% upside potential.

Via InvestorPlace

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

April 17, 2023

From Nkarta, Inc.

Via GlobeNewswire

3 Biotech Stocks to Watch for Potential Breakthroughs ↗

April 11, 2023

These biotech stocks have significant upside and realistic breakthrough chances in the current and distant future.

Via InvestorPlace

NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday ↗

March 17, 2023

Wells Fargo raised the price target for Warner Bros. Discovery, Inc. (NASDAQ: WBD) from $13 to $20. Wells Fargo analyst Steven Cahall upgraded the stock from Equal-Weight to Overweight. Warner Bros....

Via Benzinga

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

March 16, 2023

From Nkarta, Inc.

Via GlobeNewswire

EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank? ↗

January 03, 2023

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022 ↗

December 22, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 08, 2022

During Thursday's trading, 138 companies set new 52-week lows.

Via Benzinga

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.

Via TheNewswire.com

What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers

December 06, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday ↗

December 05, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Nkarta Stock (NKTX) Is Volatile During Monday's Session? ↗

December 05, 2022

Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

December 05, 2022

The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today!

Via InvestorPlace

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

December 05, 2022

From Nkarta, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.